Monograph was founded to invest in life sciences companies that seek to create new or improved therapeutics, diagnostics and related technology-enabled business services which enhance healthcare outcomes. With primary offices in London, San Francisco and Dallas-Fort Worth, Monograph bridges opportunities across North America, the United Kingdom and Europe, bringing deep experience, relationships, and capabilities to help these companies scale. The Monograph team combines decades of experience in biomedical research and clinical medicine with over 55 years of investing experience in the healthcare industry cumulatively across the Monograph Partners. This experience allows Monograph to actively contribute to the growth of nascent organizations into promising biotechnology and related life sciences businesses. Monograph routinely sees opportunities it believes could contribute to transformational healthcare outcomes.
| Website | https://monograph.bio/ |
| Employees | 21 (13 on RocketReach) |
| Founded | 2021 |
| Industry | Venture Capital and Private Equity Principals |
| Keywords | Life Sciences Venture Capital, Biotech Venture Capital, Healthcare Venture Capital, Early Stage Biotech, Seed Funding Biotech, Drug Discovery Investment, Medical Device Funding, Biotech Startups, Healthcare Innovation |
| Competitors | Verily, Avidity Biosciences, Inc., Zymeworks Inc., CureVac, Moderna Therapeutics, Amgen, Zymergen, Inc., bluebird bio, Sierra Oncology, Intellia Therapeutics, Inc. +30 more (view full list) |
Looking for a particular Monograph Capital employee's phone or email?
Charles Conn is the Co-founder and Partner, Monograph Capital of Monograph Capital.
13 people are employed at Monograph Capital.
Monograph Capital is based in London, England.